Mark Baldry - Oct 31, 2023 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Chief Commercial Officer
Signature
/s/ Adam S. Mostafa, attorney-in-fact
Stock symbol
XFOR
Transactions as of
Oct 31, 2023
Transactions value $
$0
Form type
4
Date filed
11/2/2023, 05:00 PM
Previous filing
Nov 4, 2022
Next filing
Nov 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XFOR Common Stock Award $0 +34.9K $0.00 34.9K Oct 31, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.